Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SML001
MIFTS: 57

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Small Cell Carcinoma

About this section

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15
Small Cell Carcinoma, Intermediate Cell 12 73
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 73
Carcinoma, Small Cell 73

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Skin diseases Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050685
NCIt 50 C4099
SNOMED-CT 68 5958006
Sources

Summaries for Small Cell Carcinoma

About this section
Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to lung combined type small cell carcinoma and ureter small cell carcinoma. An important gene associated with Small Cell Carcinoma is ENO2 (Enolase 2), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Irinotecan and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include lung, ovary and cervix, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Sources

Related Diseases for Small Cell Carcinoma

About this section

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Benign Neoplasm
Basal Cell Carcinoma Large Cell Carcinoma
Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 34.2 NCAM1 SYP
2 ureter small cell carcinoma 34.0 CHGA SYP
3 gallbladder small cell carcinoma 33.7 CHGA ENO2 NCAM1 SYP
4 gastric small cell carcinoma 33.6 CHGA ENO2 NCAM1 PTPRC SYP
5 small cell carcinoma of the bladder 33.6 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
6 endometrial small cell carcinoma 33.4 ENO2 KIT NCAM1 PDGFRA PTPRC SYP
7 prostate small cell carcinoma 33.4 ENO2 KIT KLK3 NKX2-1 PTEN SYP
8 cervix small cell carcinoma 33.4 CDKN2A CHGA ENO2 NCAM1 SYP TP53
9 small cell cancer of the lung 31.8 CALCA CDKN2A CHGA EGFR ENO2 KIT
10 penile cancer 31.4 CDKN2A EGFR TP53
11 merkel cell carcinoma 31.4 CHGA ENO2 KIT KRT20 KRT7 NCAM1
12 adenocarcinoma 30.5 CDKN2A EGFR KIT PTEN TP53
13 rhabdoid cancer 30.2 ENO2 SMARCA4 SYP TP53
14 pulmonary large cell neuroendocrine carcinoma 30.2 CHGA ENO2 SYP
15 carcinoid syndrome 30.2 CALCA CHGA ENO2 SYP
16 ovarian mucinous neoplasm 30.0 KRT20 KRT7 SYP
17 in situ carcinoma 29.9 CDKN2A EGFR TP53
18 tubular adenocarcinoma 29.8 CHGA KRT20 SYP
19 teratoma 29.8 ENO2 KIT KRT7 NKX2-1 SYP TP53
20 large cell neuroendocrine carcinoma 29.8 CHGA EGFR ENO2 KIT KRT20 KRT7
21 follicular adenoma 29.8 CALCA NKX2-1 PTEN
22 linitis plastica 29.8 KRT20 KRT7
23 lung oat cell carcinoma 29.7 CALCA CHGA ENO2
24 atypical teratoid rhabdoid tumor 29.7 SMARCA4 SYP TP53
25 mucinous cystadenocarcinoma 29.7 KRT20 KRT7 PTPRC
26 achalasia 29.7 ENO2 KIT TP53
27 large cell carcinoma 29.6 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
28 dermoid cyst 29.6 CHGA KIT KRT20 KRT7
29 cystic teratoma 29.6 ENO2 KRT20 KRT7 NKX2-1 SYP TP53
30 basaloid squamous cell carcinoma 29.6 CDKN2A EGFR ENO2 KRT7 SYP TP53
31 rhabdomyosarcoma 29.5 ENO2 PDGFRA PTPRC TP53
32 pleomorphic carcinoma 29.5 EGFR KRT7 NKX2-1 TP53
33 lung cancer susceptibility 3 29.5 CDKN2A EGFR KRT20 KRT7 NKX2-1 TP53
34 suppression of tumorigenicity 12 29.5 CHGA KLK3 PTEN TP53
35 endocervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
36 cervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
37 pulmonary blastoma 29.4 CHGA EGFR NKX2-1 SYP TP53
38 breast adenocarcinoma 29.4 CALCA EGFR PTEN TP53
39 barrett esophagus 29.4 CDKN2A KRT20 KRT7 TP53
40 li-fraumeni syndrome 29.4 CDKN2A EGFR PTEN TP53
41 bladder urothelial carcinoma 29.4 KLK3 KRT20 KRT7 TP53
42 renal cell carcinoma, nonpapillary 29.4 EGFR KIT KRT20 KRT7 NKX2-1
43 adenosquamous carcinoma 29.3 EGFR KIT KRT7 NKX2-1 TP53
44 adenoid cystic carcinoma 29.3 KIT KRT20 KRT7 PTEN SMARCA2 TP53
45 glioblastoma 29.3 CDKN2A EGFR PDGFRA PTEN TP53
46 chordoma 29.1 CDKN2A EGFR KRT7 PDGFRA PTEN
47 lung cancer 29.1 CDKN2A CHGA EGFR ENO2 KIT KRT20
48 glioblastoma multiforme 29.0 CDKN2A EGFR PDGFRA PTEN TP53
49 neuroendocrine tumor 29.0 CALCA CHGA ENO2 KRT20 KRT7 NCAM1
50 transitional cell carcinoma 29.0 CDKN2A EGFR ENO2 KRT20 KRT7 PTEN

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma
Sources

Symptoms & Phenotypes for Small Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 CDKN2A CHGA KIT KLK3 KRT7 NKX2-1

MGI Mouse Phenotypes related to Small Cell Carcinoma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDKN2A EGFR ENO2 KIT KRT7 NCAM1
2 growth/size/body region MP:0005378 10.33 CDKN2A CHGA EGFR ENO2 KIT NKX2-1
3 homeostasis/metabolism MP:0005376 10.31 CDKN2A CHGA EGFR KIT KRT7 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.3 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
5 digestive/alimentary MP:0005381 10.27 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
6 mortality/aging MP:0010768 10.27 CDKN2A CHGA EGFR KIT NCAM1 NKX2-1
7 nervous system MP:0003631 10.25 CDKN2A CHGA EGFR ENO2 KIT NCAM1
8 cardiovascular system MP:0005385 10.24 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
9 neoplasm MP:0002006 10.16 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
10 integument MP:0010771 10.13 CDKN2A EGFR KIT PDGFRA PTEN SMARCA2
11 muscle MP:0005369 10.13 CDKN2A CHGA EGFR KIT PDGFRA PTEN
12 liver/biliary system MP:0005370 10.05 CDKN2A EGFR KIT PTEN PTPRC SMARCA4
13 normal MP:0002873 10.02 EGFR KIT NKX2-1 PDGFRA PTEN PTPRC
14 no phenotypic analysis MP:0003012 10.01 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
15 renal/urinary system MP:0005367 9.96 CHGA EGFR KIT KRT7 PDGFRA PTEN
16 reproductive system MP:0005389 9.81 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
17 pigmentation MP:0001186 9.8 CDKN2A EGFR KIT PDGFRA PTEN TP53
18 respiratory system MP:0005388 9.65 CDKN2A EGFR ENO2 KIT NKX2-1 PDGFRA
19 skeleton MP:0005390 9.32 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
Sources

Drugs & Therapeutics for Small Cell Carcinoma

About this section

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 446)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
2
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
6
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
7
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
8
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
9 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
17 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
18 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dopamine Agents Phase 4,Phase 3,Phase 2
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
30
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
36
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1 4342-03-4 5351166
37
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
38
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
39
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 123948-87-8, 119413-54-6 60700
40
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
41
Dalteparin Approved Phase 3 9005-49-6
42
Mesna Approved, Investigational Phase 3 3375-50-6 598
43
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
44
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
45
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 60780 44424639
46
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
47
Enoxaparin Approved Phase 3,Phase 2 9005-49-6 772
48
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 216974-75-3
49
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
50
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 846)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial;Gefitinib tablets (Yi Ruisha），First medication;Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
5 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
6 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
7 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
8 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
10 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
11 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
12 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
13 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
14 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
15 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
16 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
17 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
18 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
19 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
20 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
21 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
22 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
23 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
24 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
25 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
26 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
27 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
28 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
29 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
30 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
31 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
32 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
33 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
34 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
35 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
36 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
37 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
38 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
39 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
40 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
41 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
42 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
43 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
44 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
45 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
46 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
47 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
48 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
49 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan
50 Bioinformation Therapy for Lung Cancer Completed NCT03239171 Phase 2, Phase 3 Life information rehabilitation therapy

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Small Cell Carcinoma

About this section
Sources

Anatomical Context for Small Cell Carcinoma

About this section

MalaCards organs/tissues related to Small Cell Carcinoma:

41
Lung, Ovary, Cervix, Prostate, Pancreas, Liver, Lymph Node
Sources

Publications for Small Cell Carcinoma

About this section

Articles related to Small Cell Carcinoma:

(show top 50) (show all 1269)
# Title Authors Year
1
Primary small cell carcinoma of the ureter: Case report and review of the literature. ( 29901633 )
2018
2
Primary Mammary Small Cell Carcinoma. ( 29866240 )
2018
3
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. ( 29843803 )
2018
4
Small cell carcinoma of the stomach: A report of two cases and a review of the literature. ( 29896397 )
2018
5
Advanced small cell carcinoma of the cervix - Successful treatment with concurrent etoposide and cisplatin chemotherapy and extended field radiation: A case report and discussion. ( 29255785 )
2018
6
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
7
Ovarian Small Cell Carcinoma: A Rare Case Report and Review of Literature. ( 29731803 )
2018
8
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
9
Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). ( 29423809 )
2018
10
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
11
Cytological features of small cell carcinoma of the ovary-hypercalcemic type/malignant ovarian rhabdoid tumor in ascitic fluid. ( 29446248 )
2018
12
Successful treatment of a stage IIIC small-cell carcinoma of the ovary hypercalcemic subtype using multi-modality therapeutic approach. ( 29910829 )
2018
13
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. ( 29365144 )
2018
14
Surgery for limited-stage primary small cell carcinoma of the esophagus: is it feasible and for whom is it indicated? ( 29849202 )
2018
15
Comments on "Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425616 )
2018
16
Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. ( 29879027 )
2018
17
Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. ( 29928211 )
2018
18
Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. ( 29976037 )
2018
19
Small cell carcinoma of the urinary bladder: a Clinicopathologic and Immunohistochemical analysis of 81 cases. ( 29763719 )
2018
20
Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome. ( 29580697 )
2018
21
Response to "Comments on Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus". ( 29425617 )
2018
22
Tonsillar Small Cell Carcinoma: Potential Contribution of Human Papillomavirus. ( 29686221 )
2018
23
Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. ( 29675096 )
2018
24
Lambert-Eaton Myasthenic Syndrome Associated with Synchronous Double Cancer: A Combination of Small Cell Carcinoma of the Cervix and Breast Carcinoma. ( 29526952 )
2018
25
Combined small cell carcinoma with giant cell carcinoma component of the lung: A case successfully diagnosed by computed tomography-guided fine-needle aspiration cytology. ( 29399198 )
2018
26
Primary small cell carcinoma of the larynx. Survival time of 47 months. Case report. ( 29946458 )
2018
27
Extrapulmonary small cell carcinoma: an unfortunate case of metastatic disease. ( 29309906 )
2018
28
Concomitant small cell carcinoma and adenocarcinoma of the gallbladder: a case report. ( 29923489 )
2018
29
Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review. ( 29755405 )
2018
30
The genomic landscape of small cell carcinoma of the esophagus. ( 29728688 )
2018
31
Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). ( 29354876 )
2018
32
Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors. ( 29788963 )
2018
33
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition. ( 29440177 )
2018
34
Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. ( 29734873 )
2018
35
Orbital metastatic small cell carcinoma of the pancreas with optic nerve compression. ( 29426454 )
2018
36
Synchronous Pulmonary Adenocarcinoma and Lymph Node Small Cell Carcinoma of Unknown Primary Origin. ( 30368412 )
2018
37
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. ( 30310765 )
2018
38
A Case of Primary Pulmonary Combined Small Cell Carcinoma With Adenocarcinoma Harboring the Same KLC1-ALK Fusion in Both Histologic Components. ( 30244852 )
2018
39
Primary Gastric Small Cell Carcinoma (Presenting as Linitis Plastica) Diagnosed Using Endoscopic Ultrasound-Guided Biopsy: A Case Report. ( 30300982 )
2018
40
Ovarian small cell carcinoma in one of a pair of monozygous twins. ( 30284660 )
2018
41
Metastatic small cell carcinoma with psammoma bodies: A diagnostic pitfall. ( 28980741 )
2018
42
Combined Small Cell Carcinoma of the Lung: Is It a Single Entity? ( 29101056 )
2018
43
Upper Airway Small Cell Carcinoma. ( 29102338 )
2018
44
Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non-small cell carcinoma are found? ( 29452467 )
2018
45
Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature. ( 29487254 )
2018
46
Metastatic Small Cell Carcinoma of the Breast from Cancer of the Uterine Cervix: A Case Report. ( 29515408 )
2018
47
Small Cell Carcinoma of Prostate: A Case Report of a Patient With Concomitant Transitional Cell Cancer of the Bladder. ( 29536021 )
2018
48
A dural metastatic small cell carcinoma of the gallbladder as the first manifestation: a case report. ( 29548338 )
2018
49
Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. ( 29559559 )
2018
50
P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens. ( 29566943 )
2018
Sources

Variations for Small Cell Carcinoma

About this section
Sources

Expression for Small Cell Carcinoma

About this section
Search GEO for disease gene expression data for Small Cell Carcinoma.
Sources

Pathways for Small Cell Carcinoma

About this section

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.66 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
2
Glioma 37
Show member pathways
 12.63 CDKN2A EGFR PDGFRA PTEN TP53
3
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.57 EGFR KIT PDGFRA PTEN TP53
4
Pathways in cancer 37
12.52 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
5
Neuroscience 4
12.41 CALCA ENO2 NCAM1 NKX2-1 SYP
6
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.38 EGFR PDGFRA PTEN TP53
7
Gastric cancer 37
Show member pathways
 12.37 CDKN2A EGFR KIT PTEN SMARCA2 SMARCA4
8
MicroRNAs in cancer 37
12.31 CDKN2A EGFR PDGFRA PTEN TP53
9
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.09 EGFR PDGFRA PTEN TP53
10
AKT Signaling Pathway 67
11.98 EGFR PDGFRA PTEN TP53
11
Integrated Breast Cancer Pathway 1
11.98 EGFR PTEN SMARCA4 TP53
12
Direct p53 effectors 1
11.88 EGFR PTEN SMARCA4 TP53
13
Androgen receptor signaling pathway 1
11.75 EGFR KLK3 PTEN
14
BRCA1 Pathway 64
Show member pathways
 11.69 SMARCA2 SMARCA4 TP53
15
Innate Lymphoid Cell Differentiation Pathways 65
11.67 KIT NCAM1 PTPRC
16
Dendritic Cells Developmental Lineage Pathway 65
11.63 KIT NCAM1 PTPRC
17
Bladder cancer 37 1
11.62 CDKN2A EGFR TP53
18
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.6 NCAM1 PDGFRA SMARCA4 SYP
19
Transcription Ligand-dependent activation of the ESR1/SP pathway 22
Show member pathways
 11.59 EGFR SMARCA2 SMARCA4
20
Pathways Affected in Adenoid Cystic Carcinoma 1
11.54 PTEN SMARCA2 TP53
21
Cardiac Progenitor Differentiation 1
11.41 KIT NCAM1 PDGFRA
22
Glioblastoma Multiforme 64
11.4 CDKN2A EGFR PDGFRA PTEN TP53
23
Photodynamic therapy-induced AP-1 survival signaling. 1
11.33 CDKN2A EGFR PDGFRA TP53
24
Central carbon metabolism in cancer 37
10.83 EGFR KIT PDGFRA PTEN TP53
Sources

GO Terms for Small Cell Carcinoma

About this section

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 npBAF complex GO:0071564 8.96 SMARCA2 SMARCA4
2 cytoplasmic side of plasma membrane GO:0009898 8.8 KIT PTEN PTPRC

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 EGFR KIT PDGFRA PTEN TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDKN2A EGFR NKX2-1 SMARCA2 SMARCA4 TP53
3 positive regulation of gene expression GO:0010628 9.83 CDKN2A KIT NKX2-1 PTEN TP53
4 MAPK cascade GO:0000165 9.78 EGFR KIT NCAM1 PDGFRA
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.77 EGFR KIT PDGFRA
6 lung development GO:0030324 9.76 EGFR NKX2-1 PDGFRA
7 negative regulation of transcription, DNA-templated GO:0045892 9.73 CALCA CDKN2A NKX2-1 SMARCA2 SMARCA4 TP53
8 positive regulation of MAPK cascade GO:0043410 9.62 EGFR KIT PDGFRA PTPRC
9 mast cell degranulation GO:0043303 9.59 CHGA KIT
10 positive regulation of phospholipase C activity GO:0010863 9.57 KIT PDGFRA
11 replicative senescence GO:0090399 9.56 CDKN2A TP53
12 tongue development GO:0043586 9.55 EGFR KIT
13 cerebral cortex cell migration GO:0021795 9.54 EGFR NKX2-1
14 Leydig cell differentiation GO:0033327 9.52 NKX2-1 PDGFRA
15 somatic stem cell division GO:0048103 9.51 CDKN2A KIT
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.49 EGFR TP53
17 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.46 CDKN2A PTEN
18 negative regulation of cell growth GO:0030308 9.46 CDKN2A SMARCA2 SMARCA4 TP53
19 mast cell chemotaxis GO:0002551 9.4 CHGA KIT
20 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 EGFR KIT PDGFRA PTEN PTPRC
21 mast cell cytokine production GO:0032762 8.96 CHGA KIT

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 CDKN2A EGFR PTEN PTPRC TP53
2 nucleotide binding GO:0000166 9.55 EGFR KIT PDGFRA SMARCA2 SMARCA4
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR KIT PDGFRA
4 hydrolase activity, acting on acid anhydrides GO:0016817 9.37 SMARCA2 SMARCA4
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR KIT PDGFRA
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 EGFR KIT NCAM1 PDGFRA
Sources

Sources for Small Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....